Article
Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors.
Genetics in medicine : official journal of the American College of Medical Genetics - 1 Dec 2007
Thakur Mugdha, Grossman Iris, McCrory Douglas C, Orlando Lori A, Steffens David C, Cline Kathryn E, Gray Rebecca N, Farmer Jennifer, DeJesus Georgette, O'Brien Cara, Samsa Gregory, Goldstein David B, Matchar David B
Abstract excerpt
PURPOSE: Cytochrome P450 (CYP450) enzymes metabolize selective serotonin reuptake inhibitor (SSRI) drugs used in treatment of depression. Variants in these genes may impact treatment efficacy and tolerability. The purpose of this study was 2-fold: to systematically review the literature for evidence supporting CYP450 genotyping to guide SSRI treatment for major depression, and, where evidence is inadequate, to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.